Prevalence of antibiotic resistance of Pseudomonas aeruginosa in cystic fibrosis infection: A systematic review and meta-analysis

Bonyadi, Parisa; Saleh, Narjes Tehrani; Yamini, Mahsa; Dehghani, M R; Amini, Kumarss

doi:10.1016/j.micpath.2022.105461

Cited by 29 publications

(16 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis found that colistin is the most effective antibiotic for the treatment of Pseudomonas spp. Throughout the study period, colistin was the only antibiotic with a resistance rate of less than 10% (Bonyadi et al, 2022).…”

Section: The Importance Of the Polymyxins In Non-fermentative Bacteri...mentioning

confidence: 99%

An Update of Mobile Colistin Resistance in Non-Fermentative Gram-Negative Bacilli

Khuntayaporn

Thirapanmethee

Chomnawang

2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Colistin, the last resort for multidrug and extensively drug-resistant bacterial infection treatment, was reintroduced after being avoided in clinical settings from the 1970s to the 1990s because of its high toxicity. Colistin is considered a crucial treatment option for Acinetobacter baumannii and Pseudomonas aeruginosa, which are listed as critical priority pathogens for new antibiotics by the World Health Organization. The resistance mechanisms of colistin are considered to be chromosomally encoded, and no horizontal transfer has been reported. Nevertheless, in November 2015, a transmissible resistance mechanism of colistin, called mobile colistin resistance (MCR), was discovered. Up to ten families with MCR and more than 100 variants of Gram-negative bacteria have been reported worldwide. Even though few have been reported from Acinetobacter spp. and Pseudomonas spp., it is important to closely monitor the epidemiology of mcr genes in these pathogens. Therefore, this review focuses on the most recent update on colistin resistance and the epidemiology of mcr genes among non-fermentative Gram-negative bacilli, especially Acinetobacter spp. and P. aeruginosa.

show abstract

Section: The Importance Of the Polymyxins In Non-fermentative Bacteri...mentioning

confidence: 99%

An Update of Mobile Colistin Resistance in Non-Fermentative Gram-Negative Bacilli

Khuntayaporn

Thirapanmethee

Chomnawang

2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…risk ratio (RR), odds ratio [OR], risk difference and mean difference), an MA of proportions allows for pooling prevalence estimates under the assumption that prevalence follows a binomial distribution (number of events in a sample) [19,20]. These methods have suffered significant improvements in recent years [20] and are now widely used to obtain disease frequency estimates using data from different settings across various disciplines [21][22][23].…”

Section: Introductionmentioning

confidence: 99%

Uncovering the NAFLD burden in people living with HIV from high‐ and middle‐income nations: a meta‐analysis with a data gap from Subsaharan Africa

et al. 2023

View full text Add to dashboard Cite

Introduction Non‐alcoholic fatty liver disease (NAFLD) has become a significant concern among people living with HIV (PLHIV), albeit its burden remains unclear. The primary objective of this systematic review (SR) and meta‐analysis (MA) was to estimate the prevalence of NAFLD and significant fibrosis in PLHIV. The secondary objective was to determine the risk factors for NAFLD among PLHIV. Methods We searched MEDLINE and Scopus from inception to 30 December 2022 for peer‐reviewed studies that included PLHIV and reported the prevalence of NAFLD. MA of proportions was used to estimate the pooled prevalence of NAFLD and significant fibrosis. MA of pre‐calculated effect estimates examined risk factors for NAFLD in PLHIV. Results We included 24 articles published between 2009 and 2022, encompassing 6326 PLHIV. The pooled prevalence of NAFLD was 38% (95% CI: 31–45%) with high heterogeneity (I2 = 96.3%). The pooled prevalence of significant fibrosis was 13% (95% CI: 8–18%) with high heterogeneity (I2 = 92.09%). Subgroup analyses showed a NAFLD prevalence of 40% (95% CI: 24–57%) in the United States, 33% (95% CI: 31–36) in Asia, 42% (95% CI: 24–61%) in Europe and 33% (95% CI: 29–37) in South America. When stratifying by income level, NAFLD was 39% (95% CI: 31–48) prevalent in PLHIV from high‐income economies and 34% in both upper‐middle‐income (95% CI: 31–37%) and lower‐middle‐income economies (95% CI: 28–41%). Higher body mass index (BMI) (OR = 1.32, 95% CI: 1.13–1.55; I2 = 89.9%), increasing triglycerides (OR = 1.48, 95% CI: 1.22–2.79; I2 = 27.2%) and dyslipidaemia (OR = 1.89, 95% CI: 1.32–2.71; I2 = 15.5%) were all associated with higher risk‐adjusted odds of NAFLD in PLHIV. Discussion The burden of NAFLD and significant fibrosis in PLHIV is significant. Therefore, targeted efforts to screen and diagnose NAFLD in this population are needed. Health services for PLHIV could include ways to target NAFLD risk factors, screen for liver disease and implement interventions to treat those with significant fibrosis or more advanced stages of liver disease. Taking no action to address NAFLD in PLHIV should not be an option. Conclusions This SR and MA found a 38% NAFLD and 13% significant fibrosis prevalence in PLHIV. Increasing triglyceride levels, higher BMI values and dyslipidaemia were associated with higher risk‐adjusted odds of NAFLD among PLHIV.

show abstract

“…A. baumannii is an opportunistic pathogen known for its ability to form complex biofilms, which play a critical role in its pathogenesis . Similarly, P. aeruginosa is involved in chronic infections in cystic fibrosis patients …”

Section: Biofilm-forming Pathogens and Their Significancementioning

confidence: 99%

Advances in Nanotechnology for Biofilm Inhibition

et al. 2023

View full text Add to dashboard Cite

Biofilm-associated infections have emerged as a significant public health challenge due to their persistent nature and increased resistance to conventional treatment methods. The indiscriminate usage of antibiotics has made us susceptible to a range of multidrug-resistant pathogens. These pathogens show reduced susceptibility to antibiotics and increased intracellular survival. However, current methods for treating biofilms, such as smart materials and targeted drug delivery systems, have not been found effective in preventing biofilm formation. To address this challenge, nanotechnology has provided innovative solutions for preventing and treating biofilm formation by clinically relevant pathogens. Recent advances in nanotechnological strategies, including metallic nanoparticles, functionalized metallic nanoparticles, dendrimers, polymeric nanoparticles, cyclodextrin-based delivery, solid lipid nanoparticles, polymer drug conjugates, and liposomes, may provide valuable technological solutions against infectious diseases. Therefore, it is imperative to conduct a comprehensive review to summarize the recent advancements and limitations of advanced nanotechnologies. The present Review encompasses a summary of infectious agents, the mechanisms that lead to biofilm formation, and the impact of pathogens on human health. In a nutshell, this Review offers a comprehensive survey of the advanced nanotechnological solutions for managing infections. A detailed presentation has been made as to how these strategies may improve biofilm control and prevent infections. The key objective of this Review is to summarize the mechanisms, applications, and prospects of advanced nanotechnologies to provide a better understanding of their impact on biofilm formation by clinically relevant pathogens.

show abstract

Prevalence of antibiotic resistance of Pseudomonas aeruginosa in cystic fibrosis infection: A systematic review and meta-analysis

Cited by 29 publications

References 121 publications

An Update of Mobile Colistin Resistance in Non-Fermentative Gram-Negative Bacilli

An Update of Mobile Colistin Resistance in Non-Fermentative Gram-Negative Bacilli

Uncovering the NAFLD burden in people living with HIV from high‐ and middle‐income nations: a meta‐analysis with a data gap from Subsaharan Africa

Advances in Nanotechnology for Biofilm Inhibition

Contact Info

Product

Resources

About